Two weeks after winning U.S. approval as a treatment for adults with Waldenstrom’s macroglobulinemia, BeiGene’s Brukinsa scored again as a treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL).
Bristol Myers Squibb is withdrawing the biopharmaceutical giant’s Istodax from the market after recent trials showed that the peripheral T-cell lymphoma drug did not achieve primary efficacy endpoint.
China welcomed the first CAR T-cell therapy in the country following approval from the National Medical Products Administration.
Regeneron Pharmaceuticals said on May 17 the company was resuming the enrollment of patients in two studies testing the experimental lymphoma drug odronextamab after the U.S. Food and Drug Administration agreed to lift a partial clinical hold.
The U.S. Food and Drug Administration approved Pfizer’s Xalkori (crizotinib) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive.
The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
Verastem signed a definitive deal to sell the company’s global commercial and development rights for Copiktra (duvelisib) to Secura Bio.
The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.